Announcing Inaugural Deployment of Its Fotodigm Technology
SANTA MONICA, CA / ACCESSWIRE / February 22, 2018 / Parallax Health Sciences, Inc. ("Parallax" or the "Company") (OTC PINK: PRLX) is an integrated digital healthcare company focused on connected health technology-enabled, integrated care delivery products and services on a proprietary platform, that allows for remote communication, diagnosis, treatment, and monitoring of patients.The Company is pleased to announce today that its wholly-owned subsidiary, Parallax Health Management, Inc. ("PHM"), has contracted to deploy "Fotodigm," its novel patent-pending remote patient monitoring ("RPM") and Telehealth technology that provides its clients with a solution to remote care's two biggest challenges; cost and patient adoption.
"Our Chief Technology Officer of Parallax has filed patent claims on his vision of a model that challenged the status quo of current RPM offerings by leapfrogging existing complex incongruent modalities of RPM in the marketplace," stated Paul Arena, Parallax's Chief Executive Offer. Mr. Arena further stated, "As a recipient of multiple national awards on technology and the advancement of human interest, Nathaniel Bradley, Parallax's CTO, has a proven track record foundational intellectual property portfolios for Behavioral Targeted Marketing, advertising-based revenue models and Internet Accessibility that have provided consumer companies with solutions that increased their revenues by billions of dollars over the last decade."
"Fotodigm, a core component part of our Good Health Outcomes healthcare platform, is a system that allows for the remote collection, validation, and dissemination of a patient's health information remotely; allowing their doctor to evaluate patient data, make a diagnosis and prognosis to manage the patient's health more effectively," stated Mr. Bradley.
Mr. Bradley, added, "I believe my team has developed a game changing platform that fills a need for patient and caregivers alike, that is currently not available in the market. The Fotodigm technology gets us closer to our goal of providing an environment where doctors and caregivers can have easy access to their patient's data, and patients can have access to their doctors and caregivers in an easy to use format delivered at a measurable discount to competition pricing.
About Parallax Health Sciences, Inc.
Parallax Health Sciences, Inc. ("Parallax" or the "Company") (OTC Pink: PRLX), is an integrated digital healthcare company, focused on connected health technology-enabled, integrated care delivery products and services, on a proprietary platform, that allows for remote communication, diagnosis, treatment, and monitoring of patients. Parallax's novel applications patented interoperable point of care testing platforms, tests and devises, Augmented Reality driven data analytic information systems and a patent-pending patient monitoring platform is designed for the evolving needs of today's healthcare system stakeholders; patients, payers, and providers.
The Company is focused on personalized patient healthcare through its wholly owned subsidiaries, Parallax Health Management, Parallax Behavioral Health and Parallax Diagnostics.
Please visit www.parallaxhealthsciences.com, www.parallaxhealthmanagement.com, www.parallaxhealth.net
Forward-Looking Statements
This release includes forward-looking statements contained within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Parallax's expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions, are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond Parallax's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in Parallax's Form 10-K and other report filings with the SEC. Parallax is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
For more information email investorrelations@parallaxhealthsciences.com
SOURCE: Parallax Health Sciences, Inc.
